Development of a new indole derivative dry powder for inhalation for the treatment of biofilm-associated lung infections

Int J Pharm. 2023 Jan 25:631:122492. doi: 10.1016/j.ijpharm.2022.122492. Epub 2022 Dec 14.

Abstract

The aim of this work was to produce an inhalable dry powder formulation of a new anti-biofilm compound (SC38). For this purpose, chitosan was used as a polymeric carrier and l-leucine as a dispersibility enhancer. SC38 was entrapped by spray-drying into previously optimized chitosan microparticles. The final formulation was fully characterized in vitro in terms of particle morphology, particle size and distribution, flowability, aerodynamic properties, anti-biofilm activity and effects on lung cell viability. The SC38-loaded chitosan microparticles exhibited favorable aerodynamic properties with emitted and respirable fractions higher than 80 % and 45 % respectively. The optimized formulation successfully inhibited biofilm formation at microparticle concentrations starting from 20 μg/mL for methicillin-sensitive and 100 μg/mL for methicillin-resistant Staphylococcus aureus and showed a relatively safe profile in lung cells after 72 h exposure. Future in vivo tolerability and efficacy studies are needed to unravel the potential of this novel formulation for the treatment of difficult-to-treat biofilm-mediated lung infections.

Keywords: Anti-biofilm; Cell viability study; Chitosan; Design of experiments; Leucine; Spray-drying.

MeSH terms

  • Administration, Inhalation
  • Aerosols
  • Chitosan*
  • Drug Compounding
  • Dry Powder Inhalers
  • Indoles
  • Lung
  • Methicillin-Resistant Staphylococcus aureus*
  • Particle Size
  • Powders

Substances

  • Powders
  • Chitosan
  • Indoles
  • Aerosols